Similar articles for PMID: 16334133

Year	Number of Results
1962	1
1963	2
1965	1
1970	1
1971	1
1973	2
1974	1
1975	1
1979	3
1980	1
1984	1
1985	2
1986	1
1987	2
1988	2
1989	2
1990	2
1991	1
1992	7
1993	4
1994	6
1995	2
1996	2
1997	3
1998	4
1999	2
2000	3
2001	6
2002	2
2003	6
2004	2
2005	10
2006	24
2007	19
2008	16
2009	7
2010	2
2011	4
2012	3
2013	1
2015	2
2016	2
2018	2
2020	1
2022	0

1

Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin.

Koshiyama M, Kinezaki M, Uchida T, Sumitomo M. Koshiyama M, et al. Anticancer Res. 2005 Nov-Dec;25(6C):4499-502. Anticancer Res. 2005. PMID: 16334133 Free article.

2

In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.

Monk BJ, Alberts DS, Burger RA, Fanta PT, Hallum AV 3rd, Hatch KD, Salmon SE. Monk BJ, et al. Gynecol Oncol. 1998 Nov;71(2):308-12. doi: 10.1006/gyno.1998.5140. Gynecol Oncol. 1998. PMID: 9826477

3

Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.

Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, Yoshida M. Koshiyama M, et al. Anticancer Res. 2001 Jul-Aug;21(4B):2925-32. Anticancer Res. 2001. PMID: 11712788

4

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR. Kelland LR, et al. Cancer Res. 1993 Jun 1;53(11):2581-6. Cancer Res. 1993. PMID: 8388318

5

Chemosensitivity testing of paclitaxel versus docetaxel in human gynecological carcinomas: a comparison with carboplatin.

Koshiyama M, Kinezaki M, Uchida T, Sumitomo M. Koshiyama M, et al. Anticancer Res. 2006 Sep-Oct;26(5B):3655-9. Anticancer Res. 2006. PMID: 17094381 Free article.

6

Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: a comparison with cisplatin.

Koshiyama M, Fujii H, Kinezaki M, Ohgi S, Konishi M, Hidetaka N, Hayashi M, Yoshida M. Koshiyama M, et al. Anticancer Res. 2000 May-Jun;20(3A):1353-8. Anticancer Res. 2000. PMID: 10928043

7

Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.

Koshiyama M, Fujii H, Kinezaki M, Yoshida M. Koshiyama M, et al. Anticancer Res. 2001 Mar-Apr;21(2A):905-10. Anticancer Res. 2001. PMID: 11396183

8

In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.

Alberts DS, Fanta PT, Running KL, Adair LP Jr, Garcia DJ, Liu-Stevens R, Salmon SE. Alberts DS, et al. Cancer Chemother Pharmacol. 1997;39(6):493-7. doi: 10.1007/s002800050604. Cancer Chemother Pharmacol. 1997. PMID: 9118460

9

[Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].

Xiao Y, Li JD, Shi HL, Liu JH, Feng YL, Li MD. Xiao Y, et al. Ai Zheng. 2007 Apr;26(4):386-9. Ai Zheng. 2007. PMID: 17430657 Free article. Chinese.

10

[The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].

Shi W, Gu M, Liang L. Shi W, et al. Zhonghua Fu Chan Ke Za Zhi. 1996 Feb;31(2):79-82. Zhonghua Fu Chan Ke Za Zhi. 1996. PMID: 8758798 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed